Compatible cut-off values for luteinizing hormone and the luteinizing hormone/follicle-stimulating hormone ratio in diagnostic criteria of the Japan Society of Obstetrics and Gynecology for polycystic ovary syndrome.
LH
diagnostic criteria
ethnicity
polycystic ovary syndrome
testosterone
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
25
07
2022
received:
22
02
2022
accepted:
10
08
2022
pubmed:
29
10
2022
medline:
19
1
2023
entrez:
28
10
2022
Statut:
ppublish
Résumé
The abnormal secretion of luteinizing hormone (LH) is one of the typical features of polycystic ovary syndrome (PCOS) and adopted in the diagnostic criteria of the Japan Society of Obstetrics and Gynecology (JSOG). We investigated cut-off values for LH and the LH/follicle-stimulating hormone (FSH) ratio in resent two measurement systems for the diagnosis of PCOS. Ninety-nine controls and 106 patients with PCOS were enrolled. Serum LH and FSH levels were measured using an electrochemiluminescence immunoassay (ARCHITECT) and chemiluminescence immunoassay (ECLusys). We examined the distribution of the measured levels, selected the conversion closest to the standard normal distribution in the control group, and calculated mean + 1 SD values for LH and the LH/FSH ratio as candidates. Cut-off values coincided with the medians of the candidates in the two assay systems using a regression equation. We calculated the endocrinological abnormality rate in PCOS according to the JSOG criteria by abnormal LH secretion and elevated T. Cut-off values for LH (mIU/mL) and the LH/FSH ratio were 7.1 and 1.21, respectively, in ARCHITECT, and 9.9 and 1.51, respectively, in ECLusys. The detection rates of endocrinological abnormalities in PCOS were 72.2% and 70.6% in the nonoverweight/obese PCOS group and overweight/obese PCOS group, respectively, in ARCHITECT, and 69.4% and 73.5%, respectively, in ECLusys. We obtained cut-off values of LH and the LH/FSH ratio for diagnostic criteria of JSOG criteria for PCOS, that were highly compatible between two major assay systems. These cut-off values will contribute to the diagnosis of PCOS in Japan and presumably in women of Asian ethnicities.
Substances chimiques
Follicle Stimulating Hormone, Human
0
Luteinizing Hormone
9002-67-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-264Subventions
Organisme : JSPS KAKENHI
ID : JP18K09293
Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
Knochenhauer ES, Key TJ, Kahsar-Miller M, Wanggoner W, Boots LR. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.
Niki H, Matsuzaki T, Kinouchi R, et al. Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome. J Med Investig. 2014;61:65-71.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S. Prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.
Matsuzaki T, Iwasa T, Matsui S, et al. Insulin resistance and metformin treatment in women with polycystic ovary syndrome. J Mamm Ova Res. 2014;31(1):12-6.
Saito K, Matsuzaki T, Iwasa T, et al. Steroidogenic pathways involved in androgen biosynthesis in eumenorrheic women and patients with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2016;158:31-7.
Saito K, Matsuzaki T, Iwasa T, et al. Blood allopregnanolone levels in women with polycystic ovary syndrome. Clin Endocrinol. 2016;85(1):151-2.
Yoshida T, Matsuzaki T, Miyado M, et al. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr J. 2018;65(10):979-90.
Iwasa T, Matsuzaki T, Minakuchi M, et al. Diagnostic performance of serum total testosterone for Japanese patients with polycystic ovary syndrome. Endocr J. 2007;54(2):233-8.
Sugimoto O, Aono T, Kuwabara S, Taketani Y, Irahara M. The Committee for Reproductive and Endocrine in Japan Society of Obstetrics and Gynecology. Annual report (1991-1992) for the determination of diagnostic criteria for polycystic ovary syndrome. Acta Obstet Gynaecol Jpn. 1993;45:1359-67. (In Japanese).
Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 1992;167:1807-12.
Goldzieher JW. Polycystic ovarian disease. Fertil Steril. 1981;35:371-94.
Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
Majid BM, Abbas MS. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev. 2017;18:17-21.
Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: ethnic differences. J Obstet Gynaecol Res. 2019;45(12):2330-7.
Wang ET, Kao CN, Shinkai K, Pasch L, Cedars MI, Huddleston HG. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. Fertil Steril. 2013;100:214-8.
Mizunuma H, Irahara M, Kugu K, et al. The Committee for Reproductive and Endocrine in Japan Society of Obstetrics and Gynecology: annual report (2005-2006) of the revised diagnostic criteria for polycystic ovary syndrome. Acta Obstet Gynaecol Jpn. 2007;59:868-86. (In Japanese).
Kubota T. Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reprod Med Biol. 2013;12(3):71-7. https://doi.org/10.1007/s12522-013-0145-1
Iwasa T, Matsuzaki T, Tanaka N, et al. Comparison and problems of measured values of LH, FSH, and PRL among measurement systems. Endocr J. 2006;53:101-9.
Iwasa T, Matsuzaki T, Murakami M, et al. Reproducibility of luteinizing hormone hypersecretion in different phases of the menstrual cycle in polycystic ovary syndrome. J Obstet Gynaecol Res. 2009;35(3):514-9.
ECLusys LH attached document (Roche Diagnostics K.K., Japan).
ECLusys FSH II attached document (Roche Diagnostics K.K., Japan).
ECLusys TESTO II attached document (Roche Diagnostics K.K., Japan).
Kinouchi R, Matsuzaki T, Iwasa T. Setting of normal range of serum total testosterone, LH and FSH in ECLusys measuring system. Igaku Yakugaku. 2010;64:87-93. [In Japanese].
Legro RS, Arslanian SA, Ehrmann DA. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98:4565-92.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract. 2015;21(11):1291-300.
Teede HJ, Misso ML, Costello MF. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602-18.
Matsuzaki T, Iwasa T, Kawakita T, et al. Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia. Reprod Med Biol. 2018;17(3):325-8.
Matsuzaki T, Iwasa T, Yanagihara R, et al. Pilot study of the optimal protocol of low dose step-up follicle stimulating hormone therapy for infertile women. Reprod Med Biol. 2018;17(3):315-24.
Dokras A, Stener-Victorin E, Yildiz BO, et al. Androgen excess-polycystic ovary syndrome society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril. 2018;109(5):888-99.
Azziz R, Carmina E, Dewailly D, et al. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.
Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91(3):781-5.
Welt CK, Arason G, Gudmundsson JA. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab. 2006;91:4361-8.
Osuga Y, Akira S, Irahara M, et al. Annual report of reproductive endocrinology committee, Japan Society of Obstetrics and Gynecology, 2019. J Obstet Gynaecol Res. 2019;45(10):1975-9.
Matsuzaki T, Tungalagsuvd A, Iwasa T, et al. Kisspeptin mRNA expression is increased in the posterior hypothalamus in the rat model of polycystic ovary syndrome. Endocr J. 2017;64(1):7-14.
Tay CT, Hart RJ, Hickey M, et al. Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med. 2020;18(1):389.
Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32(8):1716-22.
Matsuzaki T, Munkhzaya M, Iwasa T, et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J. 2017;64(5):531-41.
Zhao Y, Wang C, Liang Z, Liu X. Diagnostic value of anti-Mullerian hormone as a biomarker for polycystic ovary syndrome: a meta-analysis update. Endocr Pract. 2019;25(10):1056-66.
Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014;29(4):791-801.
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-55.
Skiba MA, Islam RM, Bell RJ, Davis SR. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(6):694-709.